VNRX logo

VOLITIONRX LTD

VNRXNYSE AMERICAN
๐Ÿ† #5175 by market capEarnings Mar 30US Equity
$0.16โ–ผ $0.00 (โˆ’1.58%)
Market closed ยท at close
๐Ÿ””
Track VNRX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 1.6%
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$2M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
40.0%
High Growth
๐Ÿ“ŠGross Margin
85.0%
High
๐Ÿ’ตFCF Margin
-597.6%
Thin
โš–๏ธP/S Ratio
0.6x
Cheap
Otter Score
โ€”
Insufficient data
No chart data available for VNRX.

Trading Snapshot

Day Range
$0.16 โ€“ $0.17
52-Week Range
$0.16 โ€“ $7.80
Volume (shares)
1,200,851
Avg Volume (shares)
โ€”
Shares Outstanding
12.0M
Next Earnings
2027-03-30

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$2M
P/E Ratio
-0.1
P/S Ratio
0.6x
EPS (TTM)
$-1.27
Dividend Yield
0.00%
Dilution (1yr)
+23.5%
VNRX logo

VOLITIONRX LTD

VNRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2Mโ–ฒ +40.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%โ–ฒ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$21Mโ–ผ โˆ’21.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$20Mโ–ผ โˆ’25.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
5.3Mโ–ฒ +23.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$10Mโ–ผ โˆ’$8M YoY
StockOtter ยท stockotter.space

About VOLITIONRX LTD

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

PRNewsWireยท5d ago

VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones

Peer-reviewed validation in sepsis, >95% early-stage cancer detection in a blinded cohort, a government-funded sepsis program in France, licensing discussions with more than a dozen diagnostic companies worldwide, an exp

PRNewsWireยท6d ago

Volition Expands Contract with Fujifilm to Include the Nu.Qยฎ Vet Test for Cats

Expansion extends potential use of Nu.Qยฎ technology to Japan's almost nine million cats Volition expects Nu.Qยฎ Vet Feline Test to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer H

Seeking Alphaยท9d ago

VolitionRx Limited (VNRX) Q3 2026 Earnings Call Transcript

VolitionRx Limited (VNRX) Q3 2026 Earnings Call Transcript

PRNewsWireยท10d ago

VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

PRNewsWireยท13d ago

VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update

Conference call to take place on Friday, November 13 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

PRNewsWireยท26d ago

VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

HENDERSON, Nev., Oct. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with